Cargando…

Use of Idarucizumab to Revert the Anticoagulant Effect of Dabigatran in Heart Transplant Surgery: An Institutional Experience

Heart transplant is a surgical procedure with a high risk of perioperative bleeding in patients with a previous history of sternotomy, congestive liver disease, and/or use of oral anticoagulants. Anticoagulation is usually done with coumarin agents (warfarin, acenocoumarol), while on the waiting lis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Herrera-Escandón, Álvaro, Castaño-Cifuentes, Orlando, Plata-Mosquera, Carlos A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081017/ https://www.ncbi.nlm.nih.gov/pubmed/32206355 http://dx.doi.org/10.1155/2020/6927423

Ejemplares similares

Idarucizumab to revert the anticoagulant effect of dabigatran in traumatic acute subdural haematoma: a case report of first use in Latin America
por: Izaguirre Ávila, Raúl, et al.
Publicado: (2019)

Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran
por: Sié, Pierre
Publicado: (2016)

Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran
por: Glund, Stephan, et al.
Publicado: (2019)

Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisal
por: Proietti, Marco, et al.
Publicado: (2018)

Dabigatran reversal with idarucizumab in a patient undergoing heart transplantation: first European report
por: Tralhão, António, et al.
Publicado: (2017)

Idarucizumab for the treatment of dabigatran-related nephropathy
por: Alsamarrai, Ammar, et al.
Publicado: (2020)

Idarucizumab reverses dabigatran-induced anticoagulation in treatment of gastric bleeding: A case report
por: Jia, Yu, et al.
Publicado: (2022)

Idarucizumab: A novel antidote for reversal of dabigatran
por: Rehman, Abdul, et al.
Publicado: (2016)

Reversal of Dabigatran with Idarucizumab in Acute Subarachnoid Hemorrhage
por: Balakumar, Jonathan, et al.
Publicado: (2017)

Idarucizumab (Praxbind(®)) for dabigatran reversal in patients undergoing heart transplantation: a cohort of ten patients
por: Kalmanovich, Eran, et al.
Publicado: (2021)

Reversal of Anticoagulation Effect of Dabigatran with Idarucizumab, for Thrombolysis in Acute Ischemic Stroke: Inimicus Inimico Amicus
por: Maramattom, Boby V., et al.
Publicado: (2019)

Idarucizumab as Antidote to Intracerebral Hemorrhage under Treatment with Dabigatran
por: Held, Valentin, et al.
Publicado: (2016)

The Renal Elimination Pathways of the Dabigatran Reversal Agent Idarucizumab and its Impact on Dabigatran Elimination
por: Glund, Stephan, et al.
Publicado: (2018)

Successful intravenous thrombolysis for ischemic stroke after reversal of dabigatran anticoagulation with idarucizumab: a case report
por: Agosti, Sergio, et al.
Publicado: (2017)

Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study
por: Glund, Stephan, et al.
Publicado: (2016)

Dabigatran Toxicity in Acute Kidney Injury: Hemodialysis and Idarucizumab Required
por: McBride, Lucy, et al.
Publicado: (2018)

Idarucizumab for a traumatic head injury patient taking dabigatran
por: Maruyama, Shuhei, et al.
Publicado: (2018)

Idarucizumab for Emergency Reversal of Anticoagulant Effects of Dabigatran: Interim Results of a Japanese Post-Marketing Surveillance Study
por: Yasaka, Masahiro, et al.
Publicado: (2020)

Dabigatran level monitoring prior to idarucizumab administration in patients requiring emergent cardiac surgery
por: Litwinowicz, Radoslaw, et al.
Publicado: (2017)

Intravenous Thrombolysis after Reversal of Dabigatran by Idarucizumab: A Case Report
por: Kafke, Waldemar, et al.
Publicado: (2016)

Safety of idarucizumab in the reversal of dabigatran at six tertiary care Ontario hospitals
por: Abdulrehman, Jameel, et al.
Publicado: (2021)

Extensive spontaneous cervical epidural hematoma due to oral anticoagulant (dabigatran) successfully treated with reversal agent idarucizumab alone
por: Uddin, Syed-Abdullah, et al.
Publicado: (2022)

Perioperative Myocardial Infarction Following Dabigatran Reversal With Idarucizumab in a Patient Undergoing Orthotopic Liver Transplantation
por: Barroso, Alex, et al.
Publicado: (2023)

Safety and timing of resuming dabigatran after major gastrointestinal bleeding reversed by idarucizumab
por: Riario Sforza, Gian Galeazzo, et al.
Publicado: (2018)

Immediate Reversal of Dabigatran by Idarucizumab Prior to Laboratory and Imaging Results in Acute Stroke
por: Hieber, Maren, et al.
Publicado: (2019)

Real‐world use of idarucizumab for dabigatran reversal in three cases of serious bleeding
por: Gendron, Nicolas, et al.
Publicado: (2017)

Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies
por: Norris, Stephen, et al.
Publicado: (2017)

Intravenous Thrombolysis After Dabigatran Reversal by Idarucizumab: A Systematic Review of the Literature
por: Frol, Senta, et al.
Publicado: (2021)

Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Thrombolytic Therapy
por: Kikule, Ilga, et al.
Publicado: (2022)

Authors’ Reply to Kamel et al.: “Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study”
por: Glund, Stephan, et al.
Publicado: (2016)

In a trauma experimental pig model prothrombin complex concentrates and a specific antidote (idarucizumab) are effective to reverse the anticoagulant effects of dabigatran
por: Grottke, O, et al.
Publicado: (2014)

Use of Idarucizumab for dabigatran reversal: Emergency department experience in two cases with subdural haematoma
por: Edwards, Gail, et al.
Publicado: (2017)

Volume replacement strategies do not impair the binding of dabigatran to idarucizumab: Porcine model of hemodilution
por: Grottke, Oliver, et al.
Publicado: (2019)

First Reported Case of Hemopericardium Related to Dabigatran Use Reversed by New Antidote Idarucizumab
por: Song, Steven, et al.
Publicado: (2017)

Effective Removal of Dabigatran by Idarucizumab or Hemodialysis: A Physiologically Based Pharmacokinetic Modeling Analysis
por: Fuhr, Laura Maria, et al.
Publicado: (2020)

Difficult reversal of dabigatran with idarucizumab in a multiple-trauma patient: A question of dose?
por: Ströhle, Mathias, et al.
Publicado: (2021)

Use of a specific antidote to dabigatran (idarucizumab) reduces blood loss and mortality in dabigatran-induced and trauma-induced bleeding in pigs
por: Honickel, M, et al.
Publicado: (2014)

Reversal of the Anticoagulation Effects of Dabigatran Etexilate by Idarucizumab in Three Patients Needing Urgent Surgical Intervention and One Case of Intravenous Thrombolysis in Ischaemic Stroke
por: von Wowern, Fredrik, et al.
Publicado: (2017)

Intravenous thrombolysis in acute ischemic stroke after dabigatran reversal with idarucizumab – a case report
por: Mutzenbach, Johannes Sebastian, et al.
Publicado: (2016)

Systemic thrombolysis and endovascular thrombectomy in severe acute ischemic stroke after dabigatran reversal with idarucizumab
por: Binet, Quentin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2mqeq5o0q1vo648ij1vsis6p67